Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial

References

• KasteleinJJThe future of best practiceAtherosclerosis1999143Suppl 1 S17 S2110382834
   PubMed Web of Science ®Google Scholar
• BadimonJJFusterVChesebroJHBadimonLCoronary atherosclerosis. A multifactorial diseaseCirculation1993873 Suppl II3 II168443920
   PubMed Web of Science ®Google Scholar
• IsoHJacobsDRJrWentworthDNeatonJDCohenJDSerum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trialN Engl J Med198932014 904 9102619783
   PubMed Web of Science ®Google Scholar
• KannelWBCastelliWPGordonTMcNamaraPMSerum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham studyAnn Intern Med1971741 1 125539274
   PubMed Web of Science ®Google Scholar
• SytkowskiPAKannelWBD’AgostinoRBChanges in risk factors and the decline in mortality from cardiovascular disease. The Framingham heart studyN Engl J Med199032223 1635 16412288563
   PubMed Web of Science ®Google Scholar
• SeverPSDahlöfBPoulterNRASCOT investigatorsPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet20033619364 1149 115812686036
   PubMed Web of Science ®Google Scholar
• PedersenTROlssonAGFaergemanOLipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)Circulation19989715 1453 14609576425
   PubMed Web of Science ®Google Scholar
• WatersDDGuytonJRHerringtonDMMcGowanMPWengerNKShearCTNT Steering Committee Members and InvestigatorsTreating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?Am J Cardiol2004932 154 15814715339
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaborationBaigentCBlackwellLEmbersonJEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsLancet20103769753 1670 168121067804
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation200210625 3143 342112485966
   PubMed Web of Science ®Google Scholar
• IstvanESDeisenhoferJStructural mechanism for statin inhibition of HMG-CoA reductaseScience20012925519 1160 116411349148
   PubMed Web of Science ®Google Scholar
• European Association for Cardiovascular Prevention & RehabilitationReinerZCatapanoALDe BackerGESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 CommitteesESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Eur Heart J20113214 1769 181821712404
   PubMedGoogle Scholar
• ColhounHMBetteridgeDJDurringtonPNCARDS investigatorsPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet20043649435 685 696
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAMercourisBRTreatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) studyCurr Med Res Opin2002184 220 22812201623
   PubMed Web of Science ®Google Scholar
• BallantyneCMHoogeveenRCRole of lipid and lipoprotein profiles in risk assessment and therapyAm Heart J20031462 227 23312891189
   PubMed Web of Science ®Google Scholar
• KasteleinJJvan der SteegWAHolmeITNT Study GroupIDEAL Study GroupLipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatmentCirculation200811723 3002 300918519851
   PubMed Web of Science ®Google Scholar
• van der SteegWABoekholdtSMSteinEARole of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-NorfolkAnn Intern Med20071469 640 64817470832
   PubMed Web of Science ®Google Scholar
• ParishSPetoRPalmerAInternational Studies of Infarct Survival CollaboratorsThe joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controlsEur Heart J20093017 2137 214619520708
   PubMed Web of Science ®Google Scholar
• WalldiusGJungnerIApolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapyJ Intern Med20042552 188 20514746556
   PubMed Web of Science ®Google Scholar
• LeeSHChungNKwanJComparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemiaClin Ther20072911 2365 237318158077
   PubMed Web of Science ®Google Scholar
• WangKYTingCTA randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterolJpn Heart J2001426 725 73811933922
   PubMedGoogle Scholar
• BallantyneCMAbateNYuanZKingTRPalmisanoJDose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) studyAm Heart J20051493 464 47315864235
   PubMed Web of Science ®Google Scholar
• OlssonAGIstadHLuurilaORosuvastatin Investigators GroupEffects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemiaAm Heart J20021446 1044 105112486429
   PubMed Web of Science ®Google Scholar
• JonesPKafonekSLauroraIHunninghakeDComparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)Am J Cardiol1998815 582 5879514454
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHSteinEASTELLAR Study GroupComparison of the efficacy and safety of rosuvastatin versus atorvas-tatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol2003922 152 16012860216
   PubMed Web of Science ®Google Scholar
• GoldbergRBGuytonJRMazzoneTEzetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL studyMayo Clin Proc20068112 1579 158817165637
   PubMed Web of Science ®Google Scholar
• ChoYKHurSHHanCDComparison of ezetimibe/simvastatin 10/20 mg versus atorvastatin 20 mg in achieving a target low density lipoprotein-cholesterol goal for patients with very high riskKorean Circ J2011413 149 15321519514
   PubMed Web of Science ®Google Scholar
• ShepherdJHunninghakeDBBarterPMcKenneyJMHutchinsonHGGuidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goalsAm J Cardiol2003915A 11C 17C discussion 17C–19C
   Web of Science ®Google Scholar
• KimSHParkKHongSJEfficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trialClin Ther20103211 1896 190521095484
   PubMed Web of Science ®Google Scholar
• JackeviciusCAChouMMRossJSShahNDKrumholzHMGeneric atorvastatin and health care costsN Engl J Med20123663 201 20422149736
   PubMed Web of Science ®Google Scholar
• GumbsPDVerschurenWMSouvereinPCSociety already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitutionBr J Clin Pharmacol2007645 680 68517875197
   PubMed Web of Science ®Google Scholar
• CorpEVAntoniouSWrightPGKhachiHVercaerenSWaldDSUse and cost of branded and generic drugs in patients with coronary heart disease – results from a prospective survey of 1008 patients in two London hospitalsQJM200910212 843 84919828644
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med20053535 487 49716079372
   PubMed Web of Science ®Google Scholar
• GillLSantaJPeterDLKeehnJLipitor goes generic: business as usual or more big business?Ann Intern Med201215612 892 893 W31322711082
   PubMed Web of Science ®Google Scholar
• Helin-SalmivaaraAKorhonenMJAlanenTHuupponenRImpact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in FinlandJ Clin Pharm Ther2012371 58 6421410736
   PubMed Web of Science ®Google Scholar